Saturday, December 29, 2012 Friday, December 28, 2012- NVO's Ryzodeg Approved in JapanZacks (Fri, Dec 28)
- Why Aegerion Keeps Winningat Motley Fool (Fri, Dec 28)
- Merck & Co Inc (MRK): Today's Featured Drugs Laggardat TheStreet (Fri, Dec 28)
- Pfizer Playing the Right Card Amid Changing Sector Landscapeat Motley Fool (Fri, Dec 28)
- FDA's 2012 drug approvals give Mass. biotechs a strong showing (slide show)at bizjournals.com (Fri, Dec 28)
- Merck Reveals Side Effects From Niacin Studyat Forbes (Fri, Dec 28)
- Does Lilly's Pipeline Make the Grade?at Motley Fool (Fri, Dec 28)
- Fiscal Cliff Resistant Biotech Portfolio Strategy: New Molecular Diagnostics Based Oncology Therapies in the PipelineWall Street Transcript (Fri, Dec 28)
- MRK a Top 25 Dividend Giant With $4.74B Held By ETFsat Forbes (Fri, Dec 28)
- Does Lilly's Lineup Make the Grade?at Motley Fool (Fri, Dec 28)
- OPKO to Buy Brazilian CompanyZacks (Fri, Dec 28)
Wednesday, December 26, 2012- McKesson/PSS Purchase Progresses, Merck Relays FDA Warning: Healthcare Business Recapat Wall St. Cheat Sheet (Wed, Dec 26)
- Is Eli Lilly in Good Hands?at Motley Fool (Wed, Dec 26)
- This Beaten Down Drug Company Can Provide Value in 2013at Motley Fool (Wed, Dec 26)
- Outperform The Market With These 5 Large-Cap High-Yieldersat Seeking Alpha (Wed, Dec 26)
- SNY to Expand Animal Health BusinessZacks (Wed, Dec 26)
- Merck's Tredaptive Fails in StudyZacks (Wed, Dec 26)
- Opko Health's CEO Is Buying -- Should You Sell?at Motley Fool (Wed, Dec 26)
- Why You Should Buy Merckat Seeking Alpha (Wed, Dec 26)
- Merck & Co Inc Stock Buy Recommendation Reiterated (MRK)at TheStreet (Wed, Dec 26)
Add MRK News to My Yahoo!   | |
|
0.73%